Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket

Core Insights - Bio-Techne reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, exceeding the Zacks Consensus Estimate by 10.5% and improving from 40 cents in the prior year [1][10] - The company's net sales reached $297.0 million, reflecting a 9% year-over-year increase and surpassing the Zacks Consensus Estimate by 4.1% [3][10] - The operating margin expanded significantly by 202 basis points to 16% during the reported quarter [6][10] Financial Performance - Adjusted EPS for the quarter was 42 cents, while GAAP EPS was reported at 22 cents, compared to 17 cents in the same quarter last year [2][10] - Gross profit increased by 9.8% to $193.9 million, with a gross margin of 65.3%, up 50 basis points despite a 7.4% rise in cost of sales [6][10] - Selling, general and administrative expenses rose by 5% to $121.4 million, while research and development expenses totaled $25 million, up 9.2% year over year [6][10] Segment Performance - In the Protein Sciences segment, revenues were $211.6 million, a 7% increase year over year, with an 8% organic growth [4][10] - The Diagnostics and Genomics segment saw sales improve by 12% to $84.1 million, maintaining a 12% organic growth [5][10] Capital Structure - At the end of the second quarter, Bio-Techne had cash and equivalents of $177.5 million, up from $152.9 million at the end of the first quarter [7] - Long-term debt obligations decreased to $300 million from $319 million at the end of the previous quarter [7] Operational Insights - Cumulative net cash provided by operating activities was $148.2 million, compared to $142.5 million a year ago [8] - Management indicated that the start of fiscal 2025 aligned with expectations, highlighting improvements in the biopharma end-market and strong results in the cell and gene therapy business [11][10]